According to this, only the classical subtype would fit with the current WHO 2021's GBM definition, showing focal 9p21.3 homozygous deletions that target CDKN2A, in addition to chromosome 7 amplification and chromosome 10 deletion. This evidence concerns the gene CDKN2A and glioblastoma.